Last updated on June 2018

A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating The Efficacy, Safety, And Tolerability Of Cariprazine In A Dose-Reduction Paradigm In The Prevention Of Relapse In Bipolar I Disorder Patients Whose Current Episode Is Manic Or Depressive With Or Without Mixed Features

Brief description of study

The purpose of this study is to look into the safety and efficacy of cariprazine in the treatment of Bipolar I disorder. Cariprazine is approved by the U.S. Food and Drug Administration (FDA) and currently licensed in the USA for the acute treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia.

Clinical Study Identifier: TX207245

Find a site near you

Start Over